治疗幽门螺杆菌感染的研究进展

幽门螺杆菌(Hp)的治疗是临床较为棘手的问题,标准三联疗法的根除率已降至80%或更低,其疗效下降可能与Hp耐药株日益增多相关。含铋四联疗法、序贯疗法、伴同疗法和混合疗法均优于标准三联疗法。在上述方法失败后,可考虑使用含铋四联疗法(未曾使用铋剂时)或喹诺酮三联疗法的二线治疗方案。三线治疗主要根据药敏结果及经验指导治疗。总之,临床医师应当根据具体情况,规范合理地进行抗Hp治疗。

Research Progress of Anti-Helicobacter Pylori Therapy

Treatment of helicobacter pylori(Hp)infection is a very difficult clinical issue.The eradication rate of standard triple therapy for Hp has declined to 80% or less,which may be related to the increasing incidence of drug-resistant strains of Hp.Bismuth-containing quadruple therapy,sequential therapy,concomitant therapy and hybrid therapy are all superior to standard triple therapy.If the above methods fail,second-line regimens should be considered including bismuth-containing quadruple therapy(previously not treated with regimens containing bismuth)or a quinolone-based triple therapy.Third-line therapies of anti-Hp are based on results of drug-resistant tests and experience to guide the treatment.In summary,standard and reasonable anti-Hp treatment should be taken based on specific circumstances.